News

September 16, 2021

CureLab Oncology Presents at 2021 ESMO Congress

The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
August 11, 2021

Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results

Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
July 20, 2021

CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer’s, Huntington’s, and Parkinson’s Diseases

Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases
June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
March 15, 2021

CureLab Oncology adds Hong Kong to expanding scope of patent protection

Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021

CureLab Oncology Launches Veterinary Oncology Subsidiary, CureLab Veterinary

Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.
November 10, 2020
CureLab_EU

CureLab Oncology Establishes Operations in Europe

CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
October 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region

CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation
October 14, 2020

CureLab Oncology Appoints The Honorable David J. Shulkin, M.D. to its Scientific Advisory Board

Former US Secretary of Veterans Affairs and internationally known healthcare industry leader to advise on partnerships for upcoming clinical trials and market entry strategy for CureLab’s Elenagen cancer therapy
October 5, 2020

CureLab Oncology Receives Pre-IND Response from FDA Regarding Planned Trial for Triple Negative Breast Cancer

Feedback from FDA was constructive and includes recommendations to test cumulative toxicity and clinical benefits progression; this has led the company to consider a shorter trial design for Phase II.
January 20, 2020
A Disruptive Approach to Oncology Therapy Development

A Disruptive Approach to Oncology Therapy Development

CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines
April 29, 2020

CureLab Oncology’s Dr. Alex Shneider Publishes Paper: Can Melatonin Reduce the Severity of COVID-19?

Melatonin may prevent the development of severe disease symptoms in coronavirus patients, reduce the severity of their symptoms, and/or reduce the immuno-pathology of coronavirus infection on patients’ health after the active phase of the infection is over
August 11, 2021

Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results

Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
September 16, 2021

CureLab Oncology Presents at 2021 ESMO Congress

The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy